Kazia Therapeutics (NASDAQ:KZIA) Cut to Neutral at HC Wainwright

HC Wainwright cut shares of Kazia Therapeutics (NASDAQ:KZIA – Get Rating) from a buy rating to a neutral rating in a report issued on Tuesday, MarketBeat Ratings reports.

Kazia Therapeutics Stock Up 4.8 %

Shares of Kazia Therapeutics stock opened at $1.86 on Tuesday. Kazia Therapeutics has a 12-month low of $1.63 and a 12-month high of $12.28. The stock has a 50 day moving average price of $4.29 and a two-hundred day moving average price of $5.95.

Hedge Funds Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Envestnet Asset Management Inc. acquired a new position in Kazia Therapeutics Limited (NASDAQ:KZIA – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,412 shares of the company’s stock, valued at approximately $223,000. Envestnet Asset Management Inc. owned approximately 0.20% of Kazia Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.60% of the company’s stock.

About Kazia Therapeutics

(Get Rating)

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.